Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
Go back to Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate| EMERGENT BIOSOLUTIONS, Inc. (NYSE: EBS) | Delayed: 8.39 +0.38 (4.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.01 | 52 Week High | $44.38 | |||
| Open | $8.03 | 52 Week Low | $24.47 | |||
| Day High | $8.54 | P/E | 419.50 | |||
| Day Low | $8.03 | EPS | $0.02 | |||
| Volume | 670,301 | |||||
